DDInter1008 DDInter604
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Testosterone Propionate
Testosterone Propionate {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Testosterone Propionate
Testosterone Propionate {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) interacts with {v} (Gene) NR3C2
NR3C2 {u} (Gene) is bound by {v} (Compound) Drospirenone
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) is associated with {v} (Disease) polycystic ovary syndrome
polycystic ovary syndrome {u} (Disease) is palliated by {v} (Compound) Drospirenone
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) is bound by Drospirenone (Compound)
Ketoconazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Drospirenone (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) is bound by Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) is bound by Testosterone Propionate (Compound) and Testosterone Propionate (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Testosterone Propionate (Compound) and Testosterone Propionate (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) interacts with NR3C2 (Gene) and NR3C2 (Gene) is bound by Drospirenone (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) is associated with polycystic ovary syndrome (Disease) and polycystic ovary syndrome (Disease) is palliated by Drospirenone (Compound)